Ot­su­ka ter­mi­nates Alzheimer's ag­i­ta­tion drug af­ter failed Phase 3

Ot­su­ka end­ed de­vel­op­ment of AVP-786 af­ter the ex­per­i­men­tal Alzheimer’s dis­ease treat­ment failed a late-stage study ear­li­er this year.

The com­pa­ny made the de­ci­sion to ter­mi­nate …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER